Foresight Diagnostics
Foresight Diagnostics: World's most sensitive liquid biopsy provider, detecting early cancer relapse.
Founded
2020Foresight Diagnostics: World's most sensitive liquid biopsy provider, detecting early cancer relapse.
PhasED-Seq detects circulating tumor DNA by tracking two or more tumor-associated variants on the same DNA molecule, which reduces background error compared with single-variant sequencing. Foresight CLARITY applies this approach to minimal residual disease and is described as able to measure ctDNA below one part per million, including when levels are very low after treatment.
In B-cell lymphoma, end-of-treatment studies found MRD assessment more prognostic than PET/CT in discordant cases, while solid-tumor studies compared favorably with first-generation SNV methods. The advantage is most pertinent to research and treatment-development settings where conventional imaging or less-sensitive sequencing can miss small residual disease burdens.
Oncology research and drug development are exploring ctDNA-MRD beyond recurrence monitoring, including patient selection, treatment-response assessment, risk stratification and potential trial endpoints. This creates demand for sensitive assays that can measure very low residual disease, together with laboratory and clinical-development support to incorporate results into studies.
Foresight works in this translational segment through fixed-panel lymphoma testing, personalized solid-tumor research assays, centralized laboratory capacity and services spanning trial execution and diagnostic development. Its stated applications focus on research and clinical development programs, positioning the offering around evidence generation and test development rather than broad population screening.
Foresight CLARITY is an assay platform for circulating tumor DNA minimal residual disease (ctDNA-MRD), using PhasED-Seq to track tumor-specific phased variants and reduce sequencing background. Its B-cell lymphoma offering uses a fixed panel; the solid-tumor assay is personalized and presented for exploratory research.
Alongside testing, Foresight provides centralized laboratory work and expertise for biopharma diagnostic development, clinical-trial execution and translational research, while academic investigators can seek access through research proposals. The described use cases include response assessment, patient selection and relapse monitoring in lymphoma and solid-tumor studies, rather than broad population screening.